Tack血管内系统联合药物涂层球囊治疗股浅动脉及近端腘动脉的12个月结果
TOBA III研究为前瞻性多中心单臂试验,评估Tack血管内系统处理药物涂层球囊(DCB)扩张后夹层。标准长度病变(≥20且≤150mm)患者12个月一期通畅率95.0%,免于临床驱动的靶病变血运重建97.5%,免于截肢100%,生存100%(P<.0001)。长病变(>150且≤250mm)患者一期通畅率89.3%,免于靶病变血运重建96.8%,免于截肢100%。
要点
- 标准长度病变DCB后夹层使用Tack植入,12个月一期通畅率95.0%。
- 长病变患者12个月一期通畅率89.3%,免于临床驱动靶病变血运重建96.8%。
- 全人群仅1例补救性支架植入,装置成功率高。
核心结论
- Tack血管内系统联合DCB处理股浅动脉及近端腘动脉夹层安全有效,通畅率高、二次干预率低、补救支架少。
研究设计与样本
- TOBA III为前瞻性、多中心、单臂研究,共纳入201例患者,标准长度病变169例(≥20且≤150mm),长病变32例(>150且≤250mm)。
- 患者接受Medtronic IN.PACT Admiral DCB血管成形术后出现夹层,随后使用Tack植入物治疗。
- 主要终点为30天免于主要不良事件和12个月一期通畅率。
主要发现
- 标准长度病变队列12个月一期通畅率95.0%、免于临床驱动靶病变血运重建97.5%、免于截肢100%、生存100%(P<.0001)。
- 长病变患者12个月一期通畅率89.3%、免于临床驱动靶病变血运重建96.8%、免于截肢100%。
- 装置成功率在标准长度病变为95.8%(182/190),长病变为97.7%(43/44)。
- 手术成功率在标准长度病变为99.4%(168/169),长病变为100%(44/44),全人群仅1例补救性支架植入。
关键数值与推荐
- 标准长度病变定义:≥20mm且≤150mm;长病变定义:>150mm且≤250mm。
- 主要终点:30天免于主要不良事件和12个月一期通畅率。
临床怎么用
- 对于股浅动脉及近端腘动脉DCB扩张后出现夹层的患者,可考虑使用Tack血管内系统进行聚焦处理,以降低补救支架需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Tack Endovascular System (Intact Vascular, Wayne, Pa) combines low-metallic content with focal delivery to seal areas of dissection associated with balloon angioplasty. The device system is designed to treat vascular dissections in the superficial femoral and proximal popliteal arteries. Tack implants exert low radial force and are associated with minimal metal burden, which reduces the mechanical stress on the arterial wall in treating dissections after balloon angioplasty. This study investigated the safety and effectiveness of the Tack Endovascular System in patients with dissections after drug-coated balloon (DCB) angioplasty. METHODS: The Tack Optimized Balloon Angioplasty III (TOBA III) study is a prospective, multicenter, single-arm study in which patients who underwent percutaneous transluminal angioplasty with the Medtronic IN.PACT Admiral DCB (Medtronic, Dublin, Ireland) and experienced dissection after angioplasty were treated with Tack implants. The primary end points were freedom from major adverse events at 30 days and primary patency at 12 months. RESULTS: A total of 201 patients were enrolled in the trial, 169 with standard-length lesions (≥20 mm and ≤150 mm) and 32 with long-length lesions (>150 mm and ≤250 mm). Safety and effectiveness results were favorable compared with historical benchmarks at 12 months in the standard-lesion cohort. Notably, patients in the standard-lesion cohort experienced 95.0% primary patency, 97.5% freedom from clinically driven target lesion revascularization, 100% freedom from amputation, and 100% survival at 12 months (P < .0001). Primary patency in long-lesion patients was 89.3%, freedom from clinically driven target lesion revascularization was 96.8%, and freedom from amputation was 100% at 12 months. Device success was achieved in 95.8% (182/190) and 97.7% (43/44) of devices deployed into standard-lesion and long-lesion patients, respectively. Procedural success was 99.4% (168/169) and 100% (44/44) in the standard-lesion and long-lesion cohorts, respectively, with only one bailout stent placed in the entire population. CONCLUSIONS: The Tack Endovascular System is a safe and effective treatment option for patients with dissections after angioplasty in the superficial femoral and proximal popliteal arteries, with high patency, low rates of secondary intervention, and low incidence of bailout stenting when it is used in combination with DCB.
引用
- Brodmann M, Wissgott C, Brechtel K, et al. Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results. J Vasc Surg. 2020. PMID: 32414527. doi:10.1016/j.jvs.2020.01.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。